78 related articles for article (PubMed ID: 8904046)
21. Contribution of cysteine residues to the structure and function of herpes simplex virus gH/gL.
Cairns TM; Landsburg DJ; Whitbeck JC; Eisenberg RJ; Cohen GH
Virology; 2005 Feb; 332(2):550-62. PubMed ID: 15680420
[TBL] [Abstract][Full Text] [Related]
22. Pyridine N-oxide derivatives: unusual anti-HIV compounds with multiple mechanisms of antiviral action.
Balzarini J; Stevens M; De Clercq E; Schols D; Pannecouque C
J Antimicrob Chemother; 2005 Feb; 55(2):135-8. PubMed ID: 15650002
[TBL] [Abstract][Full Text] [Related]
23. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds.
Pauwels R; Balzarini J; Baba M; Snoeck R; Schols D; Herdewijn P; Desmyter J; De Clercq E
J Virol Methods; 1988 Aug; 20(4):309-21. PubMed ID: 2460479
[TBL] [Abstract][Full Text] [Related]
24. Anti-HIV-1 and HIV-2 activity of naphthalenedisulfonic acid derivatives. Inhibition of cytopathogenesis, giant cell formation, and reverse transcriptase activity.
Mohan P; Singh R; Baba M
Biochem Pharmacol; 1991 Feb; 41(4):642-6. PubMed ID: 1705124
[No Abstract] [Full Text] [Related]
25. [Preliminary screening for antiviral AIDS drugs. II. Report on fiscal year 1989].
Noro S; Sato N; Sakurada N; Fujita N; Ishizaki T; Kamimura N; Yoshida Y; Ono T; Ohtomo N; Matsuda Y
Eisei Shikenjo Hokoku; 1991; (109):107-10. PubMed ID: 1364373
[TBL] [Abstract][Full Text] [Related]
26. Tetrazolium-based colorimetric assay for the detection of HIV replication inhibitors: revisited 20 years later.
Pannecouque C; Daelemans D; De Clercq E
Nat Protoc; 2008; 3(3):427-34. PubMed ID: 18323814
[TBL] [Abstract][Full Text] [Related]
27. [Preliminary screening for antiviral AIDS drugs. I. Report on fiscal year 1988].
Miki T; Ohnuki N; Shinkai T; Yabuuchi K; Ono T; Ohtomo N; Matsuda Y; Matsuyama M; Akiyoshi K; Ohtake T
Eisei Shikenjo Hokoku; 1990; (108):128-31. PubMed ID: 1364341
[TBL] [Abstract][Full Text] [Related]
28. The phenylmethylthiazolylthiourea nonnucleoside reverse transcriptase (RT) inhibitor MSK-076 selects for a resistance mutation in the active site of human immunodeficiency virus type 2 RT.
Auwerx J; Stevens M; Van Rompay AR; Bird LE; Ren J; De Clercq E; Oberg B; Stammers DK; Karlsson A; Balzarini J
J Virol; 2004 Jul; 78(14):7427-37. PubMed ID: 15220416
[TBL] [Abstract][Full Text] [Related]
29. Mutations conferring resistance to zidovudine diminish the antiviral effect of stavudine plus didanosine.
Izopet J; Bicart-See A; Pasquier C; Sandres K; Bonnet E; Marchou B; Puel J; Massip P
J Med Virol; 1999 Dec; 59(4):507-11. PubMed ID: 10534734
[TBL] [Abstract][Full Text] [Related]
30. Predictive factors and selection of thymidine analogue mutations by nucleoside reverse transcriptase inhibitors according to initial regimen received.
Flandre P; Descamps D; Joly V; Meiffrédy V; Tamalet C; Izopet J; Aboulker JP; Brun-Vézinet F
Antivir Ther; 2003 Feb; 8(1):65-72. PubMed ID: 12713066
[TBL] [Abstract][Full Text] [Related]
31. Protective activity of tetracycline analogs against the cytopathic effect of the human immunodeficiency viruses in CEM cells.
Lemaître M; Guétard D; Hénin Y; Montagnier L; Zerial A
Res Virol; 1990; 141(1):5-16. PubMed ID: 2326552
[TBL] [Abstract][Full Text] [Related]
32. Correlation of anti-HIV potency with lipophilicity in a series of cosalane analogs having normal alkenyl and phosphodiester chains as cholestane replacements.
Keyes RF; Golebiewski WM; Cushman M
J Med Chem; 1996 Jan; 39(2):508-14. PubMed ID: 8558520
[TBL] [Abstract][Full Text] [Related]
33. Anti-HIV activity against immunodeficiency virus type 1 (HIV-I) and type II (HIV-II) of compounds isolated from the stem bark of Combretum molle.
Asres K; Bucar F
Ethiop Med J; 2005 Jan; 43(1):15-20. PubMed ID: 16370525
[TBL] [Abstract][Full Text] [Related]
34. Didanosine, interferon-alfa and ribavirin: a highly synergistic combination with potential activity against HIV-1 and hepatitis C virus.
Klein MB; Campeol N; Lalonde RG; Brenner B; Wainberg MA
AIDS; 2003 May; 17(7):1001-8. PubMed ID: 12700449
[TBL] [Abstract][Full Text] [Related]
35. The influence of the M184V mutation in HIV-1 reverse transcriptase on the virological outcome of highly active antiretroviral therapy regimens with or without didanosine.
Sproat M; Pozniak AL; Peeters M; Winters B; Hoetelmans R; Graham NM; Gazzard BG
Antivir Ther; 2005; 10(2):357-61. PubMed ID: 15865231
[TBL] [Abstract][Full Text] [Related]
36. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
37. Synergistic anti-viral effect of oxanosine and ddI against human immunodeficiency virus.
Nakamura M; Ogawa T; Yokono A; Nakamori S; Ohno T; Umezawa K
Biomed Pharmacother; 2005; 59(1-2):47-50. PubMed ID: 15740935
[TBL] [Abstract][Full Text] [Related]
38. [Preliminary screening for antiviral AIDS drugs. III. Report on fiscal year 1990].
Ohtake T; Mori H; Morimoto M; Ueba N; Kunita N; Matsuda Y; Matsuyama M; Akiyoshi K; Noro S; Sato N
Eisei Shikenjo Hokoku; 1992; (110):88-91. PubMed ID: 1364446
[TBL] [Abstract][Full Text] [Related]
39. Protease inhibitors and prevention of cross resistance.
Levin J
AIDS Treat News; 1995 Oct; (no 232):1-3. PubMed ID: 11362875
[TBL] [Abstract][Full Text] [Related]
40. Lignified materials as medicinal resources. V. Anti-HIV (human immunodeficiency virus) activity of some synthetic lignins.
Nakashima H; Murakami T; Yamamoto N; Naoe T; Kawazoe Y; Konno K; Sakagami H
Chem Pharm Bull (Tokyo); 1992 Aug; 40(8):2102-5. PubMed ID: 1423763
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
